Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …

Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables
soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is …

Evidence from mouse chronic viral infection models suggests that CD8+ T cell subsets
characterized by distinct expression levels of the receptor PD-1 diverge in their state of …

Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …

In the tumor microenvironment, CD8+ T cells play a major role in tumor immunity. CD8+ T
cells differentiate to cytotoxic T cells, traffic into the tumor microenvironment, and exhibit …

T cells have been established as core effectors for cancer therapy; this has moved the focus
of therapeutic endeavors to effectively enhance or restore T cell tumoricidal activity rather …

Cancer progression is marked by dysfunctional tumor-infiltrating lymphocytes (TIL) with high
inhibitory receptor (IR) expression. Because IR blockade has led to clinical responses in …

T-cell Bispecific Antibodies (TCBs) elicit anti-tumor responses by cross-linking T-cells to
tumor cells and mediate polyclonal T-cell expansion that is independent of T-cell receptor …

With the development of molecular cloning technology and the deep understanding of
antibody engineering, there are diverse bispecific antibody formats from which to choose to …

Background The costimulatory receptor 4-1BB (CD137, TNFRSF9) plays an important role in
sustaining effective T cell immune responses and is investigated as target for cancer …